Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

University of Zurich

Switzerland
7 Trials1 Paper

Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

Academic Research

1 papers

Published Papers

1

Trial Involvement

7

Distinct Focus Topics

0

Latest Publication

Mar 21, 2026

Quick Facts

Type
academic
HQ
Switzerland
Website
Visit

Sponsored Trials

7
Not yet recruitingI

Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients (Keta-Care)

Start Date
Compounds
Ketamine
CompletedI

Does Serotonin System Stimulation Increase Pro-social Behavior? – A Comparative Pharmacological Neuroscientific Study in Healthy Humans

Start Date
Compounds
Psilocybin, MDMA, Placebo
CompletedNA

Characterization of Altered Waking States of Consciousness in Healthy Humans

Start Date
Compounds
Psilocybin, Placebo
CompletedII

Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

Start Date
Compounds
Psilocybin, Placebo
CompletedII

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients – Proof of Concept

Start Date
Compounds
Psilocybin, Placebo
CompletedNA

Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

Start Date
Compounds
Psilocybin, Placebo
CompletedNA

Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging

Start Date
Compounds
Placebo

Research Papers

1
Open Accessindividual

Ketamine-induced changes in accumbal glutamate and their association with altered states of consciousness

This brain imaging study (n=10) in healthy participants used magnetic resonance spectroscopy to measure glutamate levels in the nucleus accumbens before and during a single intravenous ketamine infusion (50mg/70kg). Ketamine did not significantly increase overall glutamate levels, but individual changes in glutamate were positively associated with anxious ego dissolution and reduced vigilance.

Published
Journal
Brain Research Bulletin
Authors
Gubser, L. P., Trippel, A. S., Zoelch, N., Engeli, E. J. E., Herdener, M.